• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Masimo lands clearance in U.S. and Europe | Regulatory Roundup

Masimo lands clearance in U.S. and Europe | Regulatory Roundup

October 21, 2011 By MassDevice staff

Masimo

Masimo Corp. (NDSQ:MASI) landed clearance in the U.S. and Europe for its Radical-7 non-invasive pulse oximeter with rainbow acoustic monitoring technology.

The Irvine, Calif.-based company’s system provides doctors with continuous readings of acoustic respiration rate waveform and measurements.

Masimo added a new feature called In Vivo Adjustment, not yet approved by the FDA that allows doctors to account for individual patient biases and adjust the device to readings from invasive blood analysis devices.

Sign up to get our free newsletters delivered straight to your inbox

"With the latest Radical-7, we have once again expanded what clinicians can expect from a pulse oximeter; this time by adding the ability to monitor comfortably and reliably a patient’s respiration rate. And, with In-Vivo Adjustment, clinicians can, when they need to, get very accurate measurements that are not only patient focused, but adjusted to their laboratory reference devices," said Joe Kiani, Masimo founder & CEO in prepared remarks.

Masimo posted a strong second quarter driven by a 26 percent boost in sales of its Rainbow SET pulse technology, which hit $9.1 million.

The boost might have been helped along by the long-term non-exclusive agreement Masimo reached earlier this year to integrate its rainbow SET technology into Philips Healthcare’s products.

The company followed its great second quarter earnings report by announcing that its board of directors authorized a repurchase of up to 3 million shares of the company’s common stock, effective August 12.

Regulatory Roundup

  • Steris gets the FDA green light on two new sterilization devices
    Steris landed 510(k) clearance on two new sterilization devices and one clearance for an enhancement on an existing product.
    Read more.

  • Canon’s TRX-20 tonometer lands FDA clearance
    Canon won 510(k) clearance for its TX-20 full auto tonometer, part of its line of eye care equipment.
    Read more.
  • FDA clears Segasist’s prostate software
    Canadian software company Segasist landed FDA clearance for its prostate auto-contouring software Segasist P-AC.
    Read more.
  • Delcath completes regulatory process in New Zealand
    Delcath Systems completed the New Zealand product notification process for its Hepatic Chemostat delivery system.
    Read more.

  • Health Canada approves skin cancer detection
    Verisante Technology landed Health Canada approval to market its Verisante Auro for the early detection of skin cancer.
    Read more.

  • Neoprobe receives FDA nod for Lymphoseek
    Neoprobe Corporation announced that its New Drug Application for Lymphoseek has been accepted for review by the FDA.
    Read more.

  • OncoSec Medical submits device master file to FDA
    OncoSec Medical submitted the DMF to the federal watchdog agency for its patented OncoSec Medical System.
    Read more.

Filed Under: Food & Drug Administration (FDA), News Well, Patient Monitoring Tagged With: Delcath Systems Inc., Masimo, Navidea Biopharmaceuticals, Regulatory Roundup, Steris Corp.

More recent news

  • Johnson & Johnson MedTech launches new Volt plating systems for radius, humerus
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor
  • Anaconda Biomed wins CE mark for funnel catheter
  • FDA approves Neuspera neuromod for urinary incontinence

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy